Alkermes

ACADIA Pharmaceuticals Inc.ACAD · BiotechnologySan Diego, United States

69% matchPublicAI 9/100 ▼Green 2/100

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Intra-Cellular Therapies was a U.S. biopharmaceutical company focused on developing treatments for central nervous system disorders. Its principal product, CAPLYTA (lumateperone), is used to treat schizophrenia and depressive episodes associated with bipolar disorder in adults, serving patients and mental-healthcare providers.

Neurocrine Biosciences0K6R · BiotechSan Diego, United States

67% matchPublicAI 6/100 ▼Green 3/100 ▼

Neurocrine Biosciences, Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for a range of neurological, endocrine, and psychiatric conditions. Its established portfolio offers solutions for conditions such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids. Foremost among its commercialized offerings is INGREZZA, a VMAT2 inhibitor specifically indicated for treating tardive dyskinesia. Other key commercialized therapies include ONGENTYS, a catechol-O-methyltransferase inhibitor functioning as an adjunctive treatment alongside levodopa/DOPA decarboxylase inhibitors for individuals with Parkinson's disease. Additionally, ORILISSA is available for women experiencing moderate to severe endometriosis pain, and ORIAHNN provides an oral, non-surgical option for pre-menopausal women managing heavy menstrual bleeding linked to uterine fibroids. Beyond its marketed drugs, Neurocrine Biosciences maintains a robust pipeline of investigational compounds. This includes NBI-921352, which is being developed to address both pediatric patients and adults with focal epilepsy, and NBI-827104, aimed at rare pediatric epilepsy and essential tremor. Further additions to the clinical development portfolio encompass NBI-1065845 for major depressive disorder (MDD), NBI-1065846 specifically targeting anhedonia within MDD, and NBI-118568, an agent under investigation for schizophrenia. To further its research and development efforts, the company has established strategic alliances and licensing agreements with a notable roster of partners, including Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL – Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Established in 1992, Neurocrine Biosciences, Inc. maintains its headquarters in San Diego, California.

Awakn Life Sciences Inc.BiotechnologyCanada

66% matchPrivate

Solvonis Therapeutics plc is a biopharmaceutical company that develops novel medicines for central nervous system (CNS) disorders. Its initial therapeutic focus is on treating Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with discovery programs extending into broader addiction, psychiatry, and neurology fields.

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.